Antiviral Compound Meets Phase 2 Primary Endpoint Drug Discovery & Development Chimerix Inc. announced positive results from a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients. In CMX001 Study 201, a double-blind, placebo-controlled trial ... Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in ... |
